Suppr超能文献

NOD2 激动型 muramyl dipeptides 的结构-活性关系。

Structure-activity relationship in NOD2 agonistic muramyl dipeptides.

机构信息

Department of Chemistry and Centre of Advanced Studies in Chemistry, Panjab University, Chandigarh, 160014, India.

Department of Chemistry, Mehr Chand Mahajan DAV College for Women, Chandigarh 160036, India.

出版信息

Eur J Med Chem. 2024 May 5;271:116439. doi: 10.1016/j.ejmech.2024.116439. Epub 2024 Apr 20.

Abstract

Nucleotide-binding oligomerization domain 2 (NOD2) is a receptor of the innate immune system that is capable of perceiving bacterial and viral infections. Muramyl dipeptide (MDP, N-acetyl muramyl L-alanyl-d-isoglutamine), identified as the minimal immunologically active component of bacterial cell wall peptidoglycan (PGN) is recognized by NOD2. In terms of biological activities, MDP demonstrated vaccine adjuvant activity and stimulated non-specific protection against bacterial, viral, and parasitic infections and cancer. However, MDP has certain drawbacks including pyrogenicity, rapid elimination, and lack of oral bioavailability. Several detailed structure-activity relationship (SAR) studies around MDP scaffolds are being carried out to identify better NOD2 ligands. The present review elaborates a comprehensive SAR summarizing structural aspects of MDP derivatives in relation to NOD2 agonistic activity.

摘要

核苷酸结合寡聚化结构域 2(NOD2)是先天免疫系统的一种受体,能够感知细菌和病毒感染。二肽基肽酶 4(DPP4)抑制剂是一种能够抑制二肽基肽酶 4(DPP4)活性的药物,通过抑制 DPP4 的活性,从而增加 GLP-1 的水平,发挥降血糖的作用。目前,二肽基肽酶 4(DPP4)抑制剂已被广泛应用于 2 型糖尿病的治疗,并取得了良好的疗效。

相似文献

1
Structure-activity relationship in NOD2 agonistic muramyl dipeptides.
Eur J Med Chem. 2024 May 5;271:116439. doi: 10.1016/j.ejmech.2024.116439. Epub 2024 Apr 20.
2
Further Insights on Structural Modifications of Muramyl Dipeptides to Study the Human NOD2 Stimulating Activity.
Chem Asian J. 2020 Nov 16;15(22):3836-3844. doi: 10.1002/asia.202001003. Epub 2020 Oct 20.
4
Phosphorylation of muramyl peptides by NAGK is required for NOD2 activation.
Nature. 2022 Sep;609(7927):590-596. doi: 10.1038/s41586-022-05125-x. Epub 2022 Aug 24.
5
Synthesis of biologically active biotinylated muramyl dipeptides.
Bioorg Med Chem Lett. 2010 Oct 15;20(20):6061-3. doi: 10.1016/j.bmcl.2010.08.056. Epub 2010 Aug 17.
6
Membrane targeting enhances muramyl dipeptide binding to NOD2 and Arf6-GTPase in mammalian cells.
Chem Commun (Camb). 2022 Jun 8;58(46):6598-6601. doi: 10.1039/d2cc01903e.
8
Lipophilic Muramyl Dipeptide-Antigen Conjugates as Immunostimulating Agents.
ChemMedChem. 2016 Jan 19;11(2):190-8. doi: 10.1002/cmdc.201500196. Epub 2015 Jun 9.
10
Immunomodulatory properties of novel nucleotide oligomerization domain 2 (nod2) agonistic desmuramyldipeptides.
J Med Chem. 2012 Jul 26;55(14):6478-88. doi: 10.1021/jm300503b. Epub 2012 Jul 5.

引用本文的文献

2
Muropeptides and muropeptide transporters impact on host immune response.
Gut Microbes. 2024 Jan-Dec;16(1):2418412. doi: 10.1080/19490976.2024.2418412. Epub 2024 Oct 22.
3
Distinctive Immune Signatures Driven by Structural Alterations in Desmuramylpeptide NOD2 Agonists.
J Med Chem. 2024 Oct 10;67(19):17585-17607. doi: 10.1021/acs.jmedchem.4c01577. Epub 2024 Sep 29.

本文引用的文献

2
Review: Current trends, challenges, and success stories in adjuvant research.
Front Immunol. 2023 Jan 19;14:1105655. doi: 10.3389/fimmu.2023.1105655. eCollection 2023.
3
NOD1 and NOD2 Are Potential Therapeutic Targets for Cancer Immunotherapy.
Comput Intell Neurosci. 2022 Oct 10;2022:2271788. doi: 10.1155/2022/2271788. eCollection 2022.
4
Discovery of Desmuramylpeptide NOD2 Agonists with Single-Digit Nanomolar Potency.
ACS Med Chem Lett. 2022 Jul 18;13(8):1270-1277. doi: 10.1021/acsmedchemlett.2c00121. eCollection 2022 Aug 11.
5
Toll-like receptor (TLR) agonists as a driving force behind next-generation vaccine adjuvants and cancer therapeutics.
Curr Opin Chem Biol. 2022 Oct;70:102172. doi: 10.1016/j.cbpa.2022.102172. Epub 2022 Jul 1.
6
Synthesis and biological evaluation of novel 2-azido muramyl dipeptide as NOD2 agonistic adjuvants.
Bioorg Med Chem. 2022 Jul 15;66:116781. doi: 10.1016/j.bmc.2022.116781. Epub 2022 May 2.
7
Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles.
RSC Med Chem. 2021 May 14;12(7):1065-1120. doi: 10.1039/d1md00031d. eCollection 2021 Jul 21.
8
Pattern recognition receptors in health and diseases.
Signal Transduct Target Ther. 2021 Aug 4;6(1):291. doi: 10.1038/s41392-021-00687-0.
9
Structural Fine-Tuning of Desmuramylpeptide NOD2 Agonists Defines Their Adjuvant Activity.
J Med Chem. 2021 Jun 10;64(11):7809-7838. doi: 10.1021/acs.jmedchem.1c00644. Epub 2021 May 27.
10
TLR2 Agonistic Small Molecules: Detailed Structure-Activity Relationship, Applications, and Future Prospects.
J Med Chem. 2021 Jan 14;64(1):233-278. doi: 10.1021/acs.jmedchem.0c01627. Epub 2020 Dec 21.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验